Stockpolly
Search
SPTX · NASDAQ · Biotechnology

Seaport Therapeutics (SPTX)

Develops lymphatic-targeted oral prodrugs for neuropsychiatric disorders.

$24.88
At close+1.27 (+5.38%)
Watchlist

  1. Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO

    247 WallstOther

    Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.

  2. Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week High – Here’s What Happened

    Defense WorldMarket move

    Seaport Therapeutics, Inc. (NASDAQ: SPTX - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday. The company traded as high as $25.07 and last traded at $24.40, with a volume of 98612 shares. The stock had previously closed at $24.22. Analyst Ratings Changes Several equities research analysts recently commented on

  3. Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation

    Seeking Alpha

    Seaport Therapeutics leverages its Glyph platform to transform clinically validated molecules with poor delivery into proprietary, patent-protected prodrugs, reducing biological risk. GlyphAllo's Phase 2b BUOY-1 trial in MDD targets a differentiated profile, with top-line data expected in H1 2027 and a focus on anxious distress subpopulations. GlyphAgo's strong Phase 1 PK data and platform repeatability support SPTX's strategy, with Phase 2a in GAD set for H2 2026 and registration-enabling studies to follow.

  4. Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

    GuruFocus

    [url="]Seaport Therapeutics, Inc.[/url], (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and develo

  5. Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

    Business Wire

    BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.

  6. PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

    Business Wire

    BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™.

  7. Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

    GuruFocus

    [url="]Seaport Therapeutics, Inc.[/url], (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and devel

  8. Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

    GuruFocus

    [url="]Seaport Therapeutics, Inc.[/url], (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and devel

  9. Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

    Business Wire

    BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.

  10. Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

    Business Wire

    BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers.

  11. Seaport Therapeutics to Participate in Two Upcoming Investor Conferences

    GuruFocus

    [url="]Seaport Therapeutics, Inc.,[/url] (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and devel

  12. Seaport Therapeutics to Participate in Two Upcoming Investor Conferences

    Business Wire

    BOSTON--(BUSINESS WIRE)--Seaport Therapeutics to participate in two upcoming investor conferences.

  13. Seaport Therapeutics raises about $255 million in upsized IPO

    Reuters

    Drug developer Seaport Therapeutics said on Thursday it had raised about $255 ​million in its upsized initial public ‌offering in the United States.

  14. Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering

    Business Wire

    BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering.

  15. Drug developer Seaport Therapeutics targets $912 million valuation in US IPO

    Reuters

    Drug developer Seaport Therapeutics said on Monday it ​was aiming for a valuation of $912 ‌million in its initial public offering in the United States.